Medindia

X

GeneGo Renews Its Agreement With Bayer Schering Pharma AG for Another Three Years

Tuesday, January 6, 2009 General News J E 4
Advertisement
ST. JOSEPH, Mich., Jan. 6 GeneGo, Inc., a leading providerof software and high quality manually curated databases for systems biologyand pathway analysis, today announced that Bayer Schering Pharma AG hasrenewed its MetaCore licenses for another three years. Bayer Schering Pharmahas programs for cancer, cardiovascular diseases and gynecological therapiesand GeneGo has good coverage of these diseases and others. GeneGo is also inthe process of building disease specific platforms in cancer and thecardiovascular area that include blueprint pathway maps for the disease,processes and mechanisms as well as offering public domain experimental dataand disease ontologies.

"Bayer Schering Pharma was one of our first customers and we appreciatetheir loyalty," said Julie Bryant, Vice President of Business Development atGeneGo. "MetaCore is widely used in Bayer in multiple departments includingbioinformatics, oncology, cardiology and women's health for data mining andanalysis of multiple omics experimental data such as gene expression andproteomics."

About GeneGo, Inc.

GeneGo, Inc. develops systems biology technology such as compound basedpathway analysis, cheminformatics & bioinformatics software for life scienceresearch. The original computational MetaDiscovery(TM) platform allows anintegration and expert analysis of different kinds of experimental data (mRNAexpression, proteomics, metabolomics, microRNA assays and other phenotypicdata) and relevant bioactive chemistry (metabolites, drugs, other xenobiotics)within the framework of curated biological pathways and networks. GeneGo'sflagship product, MetaCore 5.1(TM), assists pharmaceutical scientists in theareas of target selection and validation, data mining in biology,identification of biomarkers for disease states and toxicology. The secondproduct, MetaDrug 5.1(TM) is designed for prediction of human metabolism,toxicity and biological effects for novel small molecules compounds.MetaBase(TM) represents the knowledge base for MetaCore.

For more information, please visit the company's web site athttp://www.genego.com.

SOURCE GeneGo, Inc.
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
New Survey Reveals Majority of Women of Child-Bear...
S
Phase III Studies of EXPAREL(TM) (DepoBupivacaine)...